HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

PEN

Penumbra, Inc. (NYSE)

Healthcare — Medical Devices

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

Hold 2.6 / 5 14 analysts
$316.65
$-0.74 (-0.23%)
Target: $364.43 (15.1%)
Sign in to add PEN to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$12.45B
P/E Ratio (TTM)72.91
Forward P/E50.44
EPS (TTM)$4.34
Dividend Yield-
Profit Margin11.76%
Revenue Growth15.60%
ROE12.73%
Debt/Equity14.67
Recommendation Hold 2.6
Analyst Target$364.43
Analysts14
Indexes NYSE

Technical Indicators

RSI (14)38.9
Beta0.70
SMA 20-
SMA 40-
52-Week High$362.41
52-Week Low$221.26
50-Day Avg$322.10
200-Day Avg$309.00
Avg Volume416.8K
Volume368.3K

Performance Analysis

NEUTRAL

PEN presents a mixed picture with both positive and negative indicators.

~ Trading at 68% of its 52-week range.
~ RSI at 38.9 is in neutral territory.
~ Price dropped below the 50-day average but remains above the 200-day — possible short-term weakness.
- P/E of 72.9 is elevated — the market expects high growth or it may be overvalued.
~ Modest revenue growth of 15.6% year-over-year.
~ Wall Street consensus is "Hold" from 14 analysts.
+ Average analyst target of $364.43 implies 15.1% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:26 UTC

Back to Screener Export Report